Menu
← Oncology Approval Tracker
FDA DECISION ·
Cyclophosphamide injection (first generic)
cyclophosphamide · Nexus Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
The first generic of the referenced 200 mg/mL cyclophosphamide solution for labeled malignant diseases, including select lymphomas, leukemias, myeloma, neuroblastoma, ovarian and breast cancers, and retinoblastoma.
LAMPGEN ANALYSIS
Why it matters
The action expands access to a specific ready-to-dilute presentation of an established antineoplastic.
What research teams should watch
Check the reference presentation, concentration and vial handling; products that require reconstitution use different instructions.
PRIMARY RECORDS